Learn more about the APOLLOE4 study and an investigational tablet designed to slow the progression of Alzheimer’s Disease.
Alzheimer’s Disease is a progressive condition that weakens memory and other mental abilities. During the early stages of Alzheimer’s disease, common changes include frequent forgetfulness, difficulty with language, and trouble making plans or organizing. No cure exists, but current medications may temporarily help with your symptoms.
Eligible participants will receive the study drug for 18 months and close care and monitoring by an Alzheimer’s disease specialist at no cost. Reimbursement is available for study-related time and travel expenses.
Why is this study important?
Our team of medical professionals is evaluating an investigational drug that is designed to slow the progression of the disease. The study drug, ALZ-801, is a tablet that is taken twice daily. It has been well tolerated in earlier studies and may be a convenient option for Alzheimer’s patients and their families. Participating in this study, will help advance the treatment of Alzheimer’s disease.
You may be able to join the study if you are:
• Experiencing memory loss due to Alzheimer’s disease (the study doctor will be able to confirm if you have Alzheimer’s disease).
• Between 50 and 80 years of age.
• Positive for the APOE4/4 gene (genetic testing provided at no cost).
• Accompanied by a caregiver or study partner willing to attend study visits and participate with you.